Printed from Voxsanity (voxsanity.com.au) — NCT07116967 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
You have moderate-to-severe plaque psoriasis and your doctor considers you a candidate for light therapy or systemic (whole-body) medication to treat it, including a medicine called ustekinumab.
You are a current cigarette smoker.
You have been diagnosed with high blood pressure (hypertension).
You have been diagnosed with high cholesterol or high fats in the blood (hyperlipidemia).
You have Type 1 or Type 2 diabetes.
You have a history of at least one heart or blood vessel event, such as a heart attack, cardiac arrest, stroke, mini-stroke (TIA), a procedure to open blocked heart arteries, heart bypass surgery, or hospitalisation for chest pain (unstable angina or acute coronary syndrome).
You are obese.
A close blood relative (parent, sibling, or child) had heart disease or sudden death at a relatively young age — specifically a male relative under 55 or a female relative under 65.
Who may not be able to join:
You have had a heart attack, stroke, procedure to open blocked heart arteries, or a blood clot in a vein or lung within the last 90 days.
You have an unstable heart condition, such as unstable chest pain, a very fast irregular heartbeat, or you were hospitalised for a heart-related reason (such as a pacemaker being fitted or heart failure) within the last 90 days.
You currently have cancer, or have had cancer (including blood cancers) within the last 5 years — except for certain treated skin cancers (basal cell or squamous cell) or treated early-stage cervical cancer with no signs of return.
There may be additional requirements not listed here (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
The Skin Hospital, Darlinghurst, New South Wales
61286512042
St George Dermatology & Skin Cancer Centre, Kogarah, New South Wales
61295874277
Westmead Hospital, Westmead, New South Wales
61288909767
Local Institution - 0311, Woolloongabba, Queensland
Veracity Clinical Research Pty Ltd., Woolloongabba, Queensland
61730391311
Skin Health Institute Inc., Carlton, Victoria
6129623 9465
Monash Medical Centre Clayton, Clayton, Victoria
61395944876
Dr Rodney Sinclair Pty Ltd., East Melbourne, Victoria
61390130099
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT07116967
Sponsor: Bristol-Myers Squibb
Phase: Phase 3
Status: Recruiting
Condition: Psoriasis
Trial contact: 855-907-3286
More information: https://clinicaltrials.gov/study/NCT07116967
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
You have moderate-to-severe plaque psoriasis and your doctor considers you a candidate for light therapy or systemic (whole-body) medication to treat it, including a medicine called ustekinumab.
You are a current cigarette smoker.
You have been diagnosed with high blood pressure (hypertension).
You have been diagnosed with high cholesterol or high fats in the blood (hyperlipidemia).
You have Type 1 or Type 2 diabetes.
You have a history of at least one heart or blood vessel event, such as a heart attack, cardiac arrest, stroke, mini-stroke (TIA), a procedure to open blocked heart arteries, heart bypass surgery, or hospitalisation for chest pain (unstable angina or acute coronary syndrome).
You are obese.
A close blood relative (parent, sibling, or child) had heart disease or sudden death at a relatively young age — specifically a male relative under 55 or a female relative under 65.
Who may not be able to join:
You have had a heart attack, stroke, procedure to open blocked heart arteries, or a blood clot in a vein or lung within the last 90 days.
You have an unstable heart condition, such as unstable chest pain, a very fast irregular heartbeat, or you were hospitalised for a heart-related reason (such as a pacemaker being fitted or heart failure) within the last 90 days.
You currently have cancer, or have had cancer (including blood cancers) within the last 5 years — except for certain treated skin cancers (basal cell or squamous cell) or treated early-stage cervical cancer with no signs of return.
There may be additional requirements not listed here (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 12 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
🇦🇷 Argentina
🇦🇺 Australia
🇧🇪 Belgium
🇧🇷 Brazil
🇧🇬 Bulgaria
🇨🇦 Canada
🇨🇱 Chile
🇨🇳 China
🇨🇿 Czechia
🇩🇰 Denmark
🇫🇷 France
🇩🇪 Germany
🇭🇺 Hungary
🇮🇹 Italy
🇯🇵 Japan
🇲🇽 Mexico
🇵🇱 Poland
Puerto Rico
🇷🇴 Romania
🇰🇷 South Korea
🇪🇸 Spain
🇸🇪 Sweden
🇹🇼 Taiwan
🇬🇧 United Kingdom
🇺🇸 United States
8 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Composite cardiovascular adjudicated 3-point major adverse cardiovascular event (MACE) plus coronary revascularization
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.